Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options
Prior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an aggressive disease with a poor prognosis. Over the past 25 years, innovations in molecular biology, pathology, and early therapeutics have transformed the treatment landscape. With th...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-02-01
|
| Series: | Breast Cancer: Basic and Clinical Research |
| Online Access: | https://doi.org/10.1177/11782234241234418 |
| _version_ | 1797294795714985984 |
|---|---|
| author | Sarah K Premji Ciara C O’Sullivan |
| author_facet | Sarah K Premji Ciara C O’Sullivan |
| author_sort | Sarah K Premji |
| collection | DOAJ |
| description | Prior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an aggressive disease with a poor prognosis. Over the past 25 years, innovations in molecular biology, pathology, and early therapeutics have transformed the treatment landscape. With the advent of multiple HER2-directed therapies, there have been immense improvements in oncological outcomes in both adjuvant and metastatic settings. Currently, 8 HER2-targeted therapies are approved by the Food and Drug Administration (FDA) for the treatment of early-stage and/or advanced/metastatic disease. Nonetheless, approximately 25% of patients develop recurrent disease or metastasis after HER2-targeted therapy and most patients with HER2+ metastatic breast cancer (MBC) die from their disease. Given the many mechanisms of resistance to HER2-directed therapy, there is a pressing need to further personalize care for patients with HER2+ MBC, by the identification of reliable predictive biomarkers, and the development of novel therapies and combination regimens to overcome therapeutic resistance. Of particular interest are established and novel antibody-drug conjugates, as well as other novel therapeutics and multifaceted approaches to harness the immune system (checkpoint inhibitors, bispecific antibodies, and vaccine therapy). Herein, we discuss standard-of-care treatment of HER2+ MBC, including the management of breast cancer brain metastases (BCBM). Furthermore, we highlight novel treatment approaches for HER2+ MBC, including endeavors to personalize therapy, and discuss ongoing controversies and challenges. |
| first_indexed | 2024-03-07T21:36:30Z |
| format | Article |
| id | doaj.art-5395632b030745c7b6696d2e22c0f512 |
| institution | Directory Open Access Journal |
| issn | 1178-2234 |
| language | English |
| last_indexed | 2024-03-07T21:36:30Z |
| publishDate | 2024-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Breast Cancer: Basic and Clinical Research |
| spelling | doaj.art-5395632b030745c7b6696d2e22c0f5122024-02-26T12:04:24ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342024-02-011810.1177/11782234241234418Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic OptionsSarah K PremjiCiara C O’SullivanPrior to the advent of the HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an aggressive disease with a poor prognosis. Over the past 25 years, innovations in molecular biology, pathology, and early therapeutics have transformed the treatment landscape. With the advent of multiple HER2-directed therapies, there have been immense improvements in oncological outcomes in both adjuvant and metastatic settings. Currently, 8 HER2-targeted therapies are approved by the Food and Drug Administration (FDA) for the treatment of early-stage and/or advanced/metastatic disease. Nonetheless, approximately 25% of patients develop recurrent disease or metastasis after HER2-targeted therapy and most patients with HER2+ metastatic breast cancer (MBC) die from their disease. Given the many mechanisms of resistance to HER2-directed therapy, there is a pressing need to further personalize care for patients with HER2+ MBC, by the identification of reliable predictive biomarkers, and the development of novel therapies and combination regimens to overcome therapeutic resistance. Of particular interest are established and novel antibody-drug conjugates, as well as other novel therapeutics and multifaceted approaches to harness the immune system (checkpoint inhibitors, bispecific antibodies, and vaccine therapy). Herein, we discuss standard-of-care treatment of HER2+ MBC, including the management of breast cancer brain metastases (BCBM). Furthermore, we highlight novel treatment approaches for HER2+ MBC, including endeavors to personalize therapy, and discuss ongoing controversies and challenges.https://doi.org/10.1177/11782234241234418 |
| spellingShingle | Sarah K Premji Ciara C O’Sullivan Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options Breast Cancer: Basic and Clinical Research |
| title | Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options |
| title_full | Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options |
| title_fullStr | Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options |
| title_full_unstemmed | Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options |
| title_short | Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options |
| title_sort | standard of care treatment for her2 metastatic breast cancer and emerging therapeutic options |
| url | https://doi.org/10.1177/11782234241234418 |
| work_keys_str_mv | AT sarahkpremji standardofcaretreatmentforher2metastaticbreastcancerandemergingtherapeuticoptions AT ciaracosullivan standardofcaretreatmentforher2metastaticbreastcancerandemergingtherapeuticoptions |